We’d “Love” for You to Put NPC On Your Agenda at the ISPOR 20th Annual International Meeting

The National Pharmaceutical Council (NPC) is traveling to the City of Brotherly Love for the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 20th Annual International Meeting from May 16-20, 2015, at the Philadelphia Marriott Downtown. Get into the Philadelphia spirit by showing NPC researchers some “love” and attending their presentations on comparative effectiveness research (CER), biosmiliars, bundled payment design and more!

NPC Vice President of Health Services Research Kimberly Westrich, MA, will present a poster (PHP98) about NPC’s annual survey, “CER and Its Effect on the Health Care Decision-Making Environment,” on Monday, May 18, 2015, at 6:45 p.m. She will share and analyze this year’s results [also check out our March 26 webinar about the 2015 survey].

NPC Chief Science Officer Robert W. Dubois, MD, PhD, is a panelist in a discussion titled “Distinguishing Biosimilarity – How Can We Generate Real-World Evidence to Support Decision-Making?” on Tuesday, May 19, 2015, at 2:15 p.m.

Dr. Dubois will represent the biopharmaceutical industry perspective and discuss the impact that biosimilars have on health policy and industry. He will be joined by:

• Nancy A. Dreyer, PhD, MPH, senior vice president, global chief of scientific affairs, Real-World & Late Phase Research, Quintiles
• Jaclyn L Bosco, PhD, MPH, associate director of epidemiology, Real-World & Late Phase Research, Quintiles

Panelists will address topics such as interchangeability between biologics and biosimiliars, International Nonproprietary Naming, biosimilarity of different delivery mechanisms, extrapolation of indications and changes in reimbursement.

NPC Director of Research Mike Ciarametaro, MBA, is participating in a workshop session, “Design of Bundled Payment in the Ambulatory Setting of Care,” on Tuesday, May 19, 2015, at 3:45 p.m. The panel will identify when bundled payment can both constrain costs and enable high quality of care, identify key considerations that drive selection of services and reimbursement, and share case examples on bundled payment appropriateness and bundle design.

Mr. Ciarametaro will be joined by:

• Joshua T. Cohen, PhD, associate professor, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
• Lili Brillstein, MPH, director, episodes of care, Horizon Healthcare Innovations
• Michael del Aguila, PhD, vice president, HEOR US Medical, Bristol-Myers Squibb

Additional presentations on NPC-sponsored research include:

• "Improvements in Self-Reported Real-World Decision-Making Ability After Completion of a Comparative Effectiveness Research Continuing Education Certificate" (PHP134) on Monday, May 18, 2015, at 3:45 p.m.
• "When Can Pharmaceutical Companies Communicate Health Economic Claims to Payers? 10 Case Studies" (PHP170) on Monday, May 18, 2015, at 3:45 p.m.
• "How Should the FDA Regulate the Communications of Health Economic Data by Pharmaceutical Companies to Payers?" (IP6) on Tuesday, May 19, 2015, at 11:00 a.m.

Be sure to also stop by NPC’s exhibit booth #807, and check out our latest health policy research!